In summary, PD-L1 serves as a key indicator for guiding the use of immune checkpoint inhibitors, while CA125 and CEA, as classical serum tumor markers, are indispensable in auxiliary diagnosis, therapeutic efficacy monitoring, and prognostic assessment. This evidence concerns the gene CD274 and neoplasm.